PlainRecalls
FDA Drug Moderate Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx Only, 90-count bottles (NDC 51991-748-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.

Reported: January 1, 2025 Initiated: December 6, 2024 #D-0162-2025

Product Description

Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx Only, 90-count bottles (NDC 51991-748-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.

Reason for Recall

CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Details

Units Affected
76,968 bottles
Distribution
Nationwide in the US
Location
Berlin, CT

Frequently Asked Questions

What product was recalled?
Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx Only, 90-count bottles (NDC 51991-748-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.. Recalled by Breckenridge Pharmaceutical, Inc. Units affected: 76,968 bottles.
Why was this product recalled?
CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 1, 2025. Severity: Moderate. Recall number: D-0162-2025.